A high proliferation rate measured by cyclin A predicts a favourable chemotherapy response in soft tissue sarcoma patients
A high proliferation rate measured by cyclin A predicts a favourable chemotherapy response in soft tissue sarcoma patients
复制标题
DOI：
10.1038/sj.bjc.6690801
复制
发表时间：
1999-11-01
影响因子：
8.8
通讯作者：
Andersson, LC
中科院分区：
文献类型：
--
作者：
Huuhtanen, RL;Wiklund, TA;Andersson, LC
一小部分但并非微不足道的患者在接受转移性软组织肉瘤治疗后生存时间延长。这必须与大多数患者进行权衡，这些患者从治疗中获益很少，但却经历了副作用。因此，能够对那些对治疗有反应的患者进行筛查是至关重要的。由于增殖细胞比非增殖细胞对化疗更敏感，我们通过测定流式细胞术S期分数和免疫组织化学Ki-67和细胞周期蛋白A评分，测量了55例局部晚期或转移性组织肉瘤患者原发肿瘤的增殖率。S期分数或Ki-67评分不能预测化疗反应或进展树生存期。然而，高cyclin A评分与更好的化疗反应（P = 0.02）和更长的无进展生存时间（P = 0.04）相关。我们的研究结果表明，高周期蛋白a评分预测化疗敏感性。(C) 1999年癌症研究运动。
A small but not insignificant number of patients experience a prolonged survival after treatment of metastatic soft tissue sarcoma. This must be weighed against the majority of the patients who benefit little from the therapy, but nevertheless experience its side-effects. It would therefore be of utmost importance to be able to screen for those patients who respond to the treatment. Since proliferating cells are more sensitive to chemotherapy than non-proliferative cells, we measured the proliferation rate of the primary tumour of 55 son tissue sarcoma patients with locally advanced or metastatic disease by determining the flow cytometric S phase fraction and immunohistochemical Ki-67 and cyclin A scores. S phase fraction or Ki-67 score did not predict chemotherapy response or progression-tree survival. A high cyclin A score, however, correlated with a better chemotherapy response (P = 0.02) and longer progression-free survival time (P = 0.04). Our results suggest that a high cyclin A score predicts chemotherapy sensitivity. (C) 1999 Cancer Research Campaign.